Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Preventive Effects of Ramelteon on Delirium

Preventive Effects of Ramelteon on Delirium ImportanceNo highly effective interventions to prevent delirium have been identified. ObjectiveTo examine whether ramelteon, a melatonin agonist, is effective for the prevention of delirium. Design, Setting, and ParticipantsA multicenter, rater-blinded, randomized placebo-controlled trial was performed in intensive care units and regular acute wards of 4 university hospitals and 1 general hospital. Eligible patients were 65 to 89 years old, newly admitted due to serious medical problems, and able to take medicine orally. Patients were excluded from the study if they had an expected stay or life expectancy of less than 48 hours. InterventionsSixty-seven patients were randomly assigned using the sealed envelope method to receive ramelteon (8 mg/d; 33 patients) or placebo (34 patients) every night for 7 days. Main Outcomes and MeasuresIncidence of delirium, as defined by the Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition). ResultsRamelteon was associated with a lower risk of delirium (3% vs 32%; P = .003), with a relative risk of 0.09 (95% CI, 0.01-0.69). Even after risk factors were controlled for, ramelteon was still associated with a lower incidence of delirium (P = .01; odds ratio, 0.07 [95% CI, 0.008-0.54]). The Kaplan-Meier estimates of time to development of delirium were 6.94 (95% CI, 6.82-7.06) days for ramelteon and 5.74 (5.05-6.42) days for placebo. Comparison by log-rank test showed that the frequency of delirium was significantly lower in patients taking ramelteon than in those taking placebo (χ2 = 9.83; P = .002). Conclusions and RelevanceRamelteon administered nightly to elderly patients admitted for acute care may provide protection against delirium. This finding supports a possible pathogenic role of melatonin neurotransmission in delirium. Trial RegistrationUniversity Hospital Medical Information Network Clinical Trials Registry Identifier: UMIN000005591 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Psychiatry American Medical Association

Preventive Effects of Ramelteon on Delirium

Download PDF
7 pages

Loading next page...
 
/lp/american-medical-association/preventive-effects-of-ramelteon-on-delirium-bbA0m0sdeM

References (34)

Publisher
American Medical Association
Copyright
Copyright 2014 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-622X
eISSN
2168-6238
DOI
10.1001/jamapsychiatry.2013.3320
pmid
24554232
Publisher site
See Article on Publisher Site

Abstract

ImportanceNo highly effective interventions to prevent delirium have been identified. ObjectiveTo examine whether ramelteon, a melatonin agonist, is effective for the prevention of delirium. Design, Setting, and ParticipantsA multicenter, rater-blinded, randomized placebo-controlled trial was performed in intensive care units and regular acute wards of 4 university hospitals and 1 general hospital. Eligible patients were 65 to 89 years old, newly admitted due to serious medical problems, and able to take medicine orally. Patients were excluded from the study if they had an expected stay or life expectancy of less than 48 hours. InterventionsSixty-seven patients were randomly assigned using the sealed envelope method to receive ramelteon (8 mg/d; 33 patients) or placebo (34 patients) every night for 7 days. Main Outcomes and MeasuresIncidence of delirium, as defined by the Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition). ResultsRamelteon was associated with a lower risk of delirium (3% vs 32%; P = .003), with a relative risk of 0.09 (95% CI, 0.01-0.69). Even after risk factors were controlled for, ramelteon was still associated with a lower incidence of delirium (P = .01; odds ratio, 0.07 [95% CI, 0.008-0.54]). The Kaplan-Meier estimates of time to development of delirium were 6.94 (95% CI, 6.82-7.06) days for ramelteon and 5.74 (5.05-6.42) days for placebo. Comparison by log-rank test showed that the frequency of delirium was significantly lower in patients taking ramelteon than in those taking placebo (χ2 = 9.83; P = .002). Conclusions and RelevanceRamelteon administered nightly to elderly patients admitted for acute care may provide protection against delirium. This finding supports a possible pathogenic role of melatonin neurotransmission in delirium. Trial RegistrationUniversity Hospital Medical Information Network Clinical Trials Registry Identifier: UMIN000005591

Journal

JAMA Psychiatry – American Medical Association

Published: Apr 1, 2014

There are no references for this article.